Literature DB >> 7217322

High-performance liquid chromatography determination of 4'-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma.

P Farina, G Marzillo, M D'Incalci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7217322     DOI： 10.1016/s0378-4347(00)81044-0

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  15 in total

1.  In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.

Authors:  T Taki; T Ohnishi; N Arita; S Hiraga; T Hayakawa
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

2.  The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.

Authors:  D Cunningham; J Cummings; R B Blackie; L McTaggart; S W Banham; S B Kaye; M Soukop
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

3.  Drug monitoring of etoposide (VP16-213). I. A combined method of liquid chromatography and mass spectrometry.

Authors:  H Danigel; K H Pflüger; H Jungclas; L Schmidt; J Dellbrügge
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 4.  The clinical pharmacology of VM26 and VP16-213. A brief overview.

Authors:  P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

6.  Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide.

Authors:  K H Pflüger; L Schmidt; M Merkel; H Jungclas; K Havemann
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  A radioimmunoassay for VP16-213 in plasma.

Authors:  G W Aherne; V Marks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Pharmacokinetics of VP16-213 given by different administration methods.

Authors:  M D'Incalci; P Farina; C Sessa; C Mangioni; V Conter; G Masera; M Rocchetti; M B Pisoni; E Piazza; M Beer; F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice.

Authors:  T Colombo; M Broggini; L Torti; E Erba; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions.

Authors:  K H Pflüger; M Hahn; J B Holz; L Schmidt; P Köhl; H W Fritsch; H Jungclas; K Havemann
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.